https://www.cellprothera.com/en/eit-health-fast-track-programme/2024-12-20T14:35:11+01:00 https://www.cellprothera.com/en/publication-of-the-cellprothera-phase-i-iib-study-design-in-the-esc-heart-failure-journal/2024-12-20T16:03:06+01:00 https://www.cellprothera.com/en/cellprothera-signs-mou-with-shonan-kamakura-general-hospital-for-use-of-stemxpand-in-japanese-stem-cell-clinical-trial/2025-02-03T15:38:24+01:00 https://www.cellprothera.com/le-figaro-regenerer-le-coeur-grace-aux-cellules-souches/2025-02-03T15:39:27+01:00 https://www.cellprothera.com/drug-target-review-le-developpement-de-la-therapie-cellulaire-et-genique-setend-aux-indications-cardiaques/2025-02-03T15:40:06+01:00 https://www.cellprothera.com/en/drug-target-review-cell-and-gene-therapy-development-moves-into-cardiac-indications/2025-02-03T15:40:37+01:00 https://www.cellprothera.com/en/cellprothera-inches-closer-to-phase-iii-trial-for-heart-attack-cell-therapy/2025-02-03T15:41:16+01:00 https://www.cellprothera.com/euro-health-leaders-relever-les-defis-de-la-production-de-therapie-cellulaire-autologue/2025-02-03T15:41:55+01:00 https://www.cellprothera.com/en/navigating-the-challenges-of-autologous-cell-therapy-production/2025-02-03T15:42:23+01:00 https://www.cellprothera.com/en/cellprothera-shares-u-s-regulatory-progress-of-protheracytes-cell-therapy-program/2025-02-03T15:42:55+01:00 https://www.cellprothera.com/le-journal-des-entreprises-cellprothera-lance-une-etude-pour-demontrer-la-securite-et-lefficacite-de-sa-therapie-cellulaire-dans-linfarctus-severe-du-myocarde/2025-02-03T15:43:50+01:00 https://www.cellprothera.com/en/cellprothera-begins-long-term-observational-study-to-demonstrate-safety-and-efficacy-of-protheracytes-cell-therapy-in-acute-myocardial-infarction/2025-02-03T15:44:19+01:00 https://www.cellprothera.com/cellprothera-lance-une-etude-observationnelle-a-long-terme-pour-demontrer-la-securite-et-lefficacite-de-la-therapie-cellulaire-protheracytes-dans-linfarctus-severe-du-myocarde/2025-02-03T15:44:56+01:00 https://www.cellprothera.com/top-sante-infarctus-hypertension-ca-bouge-cote-traitements/2025-02-03T15:58:56+01:00 https://www.cellprothera.com/bioproduction-et-biotherapies-100-healthtech-le-live-de-france-biotech-9/2025-02-03T16:00:27+01:00 https://www.cellprothera.com/en/cellprothera-and-biocardia-collaborate-on-successful-phase-ii-trial-of-protheracytes-for-the-treatment-of-acute-myocardial-infarction/2025-02-03T15:45:54+01:00 https://www.cellprothera.com/en/cellprothera-and-biocardia-collaborate-on-phase-2-trial-of-protheracytes-to-treat-ami/2025-02-03T15:46:25+01:00 https://www.cellprothera.com/la-depeche-reparer-les-coeurs-abimes-par-un-infarctus-du-myocarde-cest-possible/2025-02-03T15:47:09+01:00 https://www.cellprothera.com/en/drug-discovery-news-a-cell-therapy-to-heal-a-broken-heart/2025-02-03T15:47:37+01:00 https://www.cellprothera.com/news-day-fr-nouvelle-etape-pour-linjection-intracardiaque-de-cellules-souches/2025-02-03T15:48:28+01:00 https://www.cellprothera.com/medscape-infarctus-du-myocarde-nouvelle-etape-pour-linjection-intracardiaque-de-cellules-souches/2025-02-03T15:49:29+01:00 https://www.cellprothera.com/en/drug-development-delivery-cellprothera-announces-positive-phase-1-2b-data-for-protheracytes-cell-therapy-in-acute-myocardial-infarction/2025-02-03T15:49:52+01:00 https://www.cellprothera.com/en/epr-cell-therapy-could-help-curb-progression-of-heart-failure/2025-02-03T15:50:30+01:00 https://www.cellprothera.com/cellprothera-annonce-les-resultats-positifs-de-lessai-clinique-de-phase-i-iib-pour-la-therapie-cellulaire-protheracytes-dans-linfarctus-du-myocarde/2025-02-03T15:50:59+01:00 https://www.cellprothera.com/en/cellprothera-announces-positive-phase-i-iib-data-for-protheracytes-cell-therapy-in-acute-myocardial-infarction/2025-02-03T15:51:25+01:00 https://www.cellprothera.com/cellprothera-communiquera-les-resultats-de-son-etude-de-phase-i-iib-sur-la-securite-et-lefficacite-des-protheracytes-issues-de-cellules-souches-cd34-autologues-dans-linfarctus-severe-du-myo/2025-02-03T15:51:53+01:00 https://www.cellprothera.com/en/cellprothera-to-share-results-from-its-phase-i-iib-study-investigating-the-safety-and-efficacy-of-protheracytes-cd34-expanded-stem-cells-in-acute-myocardial-infarction/2025-02-03T15:52:25+01:00 https://www.cellprothera.com/en/ddw-2024-predictions-experts-weigh-in-on-stem-cells/2025-02-03T15:52:53+01:00 https://www.cellprothera.com/en/european-pharmaceutical-manufacturer-optimising-time-to-market-for-innovative-cell-therapy/2025-02-03T15:53:29+01:00 https://www.cellprothera.com/journal-lalsace-trophee-des-entreprises-alsace-2024/2025-02-03T15:54:17+01:00 https://www.cellprothera.com/journal-lalsace-cellprothera-laureate-du-trophee-des-entreprises-alsace-2024-dans-la-categorie-des-startups/2025-02-03T15:54:45+01:00 https://www.cellprothera.com/en/cellprothera-collaborates-with-japanese-stem-cell-experts-at-shonan-kamakura-general-hospital-skgh-on-clinical-manufacturing-for-upcoming-autologous-stem-cell-trials-in-ischemic-diseases/2025-02-03T15:55:09+01:00 https://www.cellprothera.com/en/cellprothera-collaborates-with-japanese-stem-cell-experts/2025-02-03T15:55:34+01:00 https://www.cellprothera.com/journal-lalsace-cellprothera-nomine-pour-le-trophee-des-entreprises-categorie-startup/2025-02-03T15:55:55+01:00 https://www.cellprothera.com/mutualistes-grace-aux-cellules-souches-sanguines-nous-avons-la-capacite-de-regenerer-un-coeur-affaibli/2025-02-03T16:02:37+01:00